# Driving Simulation to Assess Non-Sedative Effects of Tolperisone

> **NCT03353922** · PHASE1 · COMPLETED · sponsor: **Neurana Pharmaceuticals, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Driving Impaired

## Interventions

- **DRUG:** Cyclobenzaprine 10 Mg Oral Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03353922
- **Lead sponsor:** Neurana Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2017-12-06
- **Final completion:** 2018-01-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353922, "Driving Simulation to Assess Non-Sedative Effects of Tolperisone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03353922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*